Advertisement
Advertisement

KTTA

KTTA logo

Pasithea Therapeutics Corp. Common Stock

0.80
USD
Sponsored
-0.04
-5.32%
May 08, 15:59 UTC -4
Closed
exchange

After-Market

0.80

0.00
+0.34%

KTTA Earnings Reports

Positive Surprise Ratio

KTTA beat 1 of 3 last estimates.

33%

Next Report

In 3 Days
Date of Next Report
May 13, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/
-$0.45
Implied change from Q4 25 (Revenue/ EPS)
--
/
-43.04%
Implied change from Q1 25 (Revenue/ EPS)
--
/
--

Pasithea Therapeutics Corp. Common Stock earnings per share and revenue

On Mar 30, 2026, KTTA reported earnings of -0.79 USD per share (EPS) for Q4 25, missing the estimate of -0.18 USD, resulting in a -330.28% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +3.75% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -0.45 USD, with revenue projected to reach -- USD, implying an decrease of -43.04% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Werewolf Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+3.68%
logo
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
logo
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
logo
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
logo
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
logo
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
logo
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
logo
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
logo
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
logo
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
FAQ
For Q4 2025, Pasithea Therapeutics Corp. Common Stock reported EPS of -$0.79, missing estimates by -330.28%, and revenue of $0.00, 0% as expectations.
The stock price moved up 3.75%, changed from $0.71 before the earnings release to $0.74 the day after.
The next earning report is scheduled for May 13, 2026.
Based on -- analysts, Pasithea Therapeutics Corp. Common Stock is expected to report EPS of -$0.45 and revenue of -- for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement